.jpeg)
Indications of talquetamab-tgvs
Talquetamab(talquetamab-tgvs)is a bispecificGPRC5DdirectedCD3 Tcell engager for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, including a proteasome inhibitor, an immunomodulator, and an antiCD38 monoclonal antibody. Tactarumab For subcutaneous injection, patients should be hospitalized for 48 hours after all doses of the escalating dose regimen. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
